Forest expects to hear from FDA "within the next few weeks" regarding its NDA for a chlorofluorocarbon-free formulation of Aerobid (flunisolide), company says. Forest hopes to launch the reformulated product in the second half of 2001. Aerobid sales for the fiscal year (ended in March) were $61 mil
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth